GW Pharmaceuticals Receives Investigational New Drug (IND) From FDA for Phase 2/3 Clinical Trial of Epidiolex(R) in the Treatment of Dravet Syndrome

[GlobeNewswire] – LONDON — GW Pharmaceuticals plc (AIM:GWP) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing, and commercializing novel … more

View todays social media effects on GWPH

View the latest stocks trending across Twitter. Click to view dashboard

See who GW is hiring next, click here to view